SCHEMBL7253156

SCHEMBL7253156

Cc1cccc(C)c1N(C(=O)C(N1CCN(CC(O)Cc2ccc3c(c2)OCO3)CC1)N1CCN(CC(O)Cc2ccc3c(c2)OCO3)CC1)c1c(C)cccc1C

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
LMNA P02545 3/20 0.45
TSHR P16473 1/20 0.45
HSD17B10 Q99714 1/20 0.45
ALOX15 P16050 1/20 0.44
CYP3A4 P08684 1/20 0.44
GAA P10253 1/20 0.44
KDM4E B2RXH2 1/20 0.43
HTT P42858 1/20 0.43
ALDH1A1 P00352 1/20 0.42
OPRM1 P35372 1/20 0.42
OPRD1 P41143 1/20 0.42
OPRK1 P41145 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6280646 0.80 CYP3A4 (0.53) KMT2AMEN1SMN1; SMN2LMNATSHR
SCHEMBL6281817 0.76 SMN1; SMN2 (0.45) KMT2AMEN1SMN1; SMN2LMNATSHR
SCHEMBL7248964 0.74 ALDH1A1 (0.53) KMT2AMEN1SMN1; SMN2LMNATSHR
SCHEMBL27777311 0.66 CHRM3 (0.56) KMT2AMEN1LMNATSHRKDM4E
SCHEMBL25183681 0.65 CYP3A4 (0.73) CYP3A4GAAKDM4EALDH1A1
SCHEMBL25190612 0.65 CYP3A4 (0.73) CYP3A4GAAKDM4EALDH1A1
SCHEMBL19354484 0.65 CYP3A4 (0.73) CYP3A4GAAKDM4EALDH1A1
SCHEMBL11698405 0.65 CYP3A4 (0.56) SMN1; SMN2TSHRHSD17B10CYP3A4ALDH1A1
SCHEMBL10726419 0.65 ADRB2 (0.60) LMNATSHRALDH1A1
SCHEMBL7267761 0.65 KDM4E (0.65) KMT2AMEN1SMN1; SMN2LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6552023-B2 N-(2,6-dimethylphenyl)-2-(4-(2-hydroxy-4-phenylbutyl) -piperazinyl)acetamide, for example; useful to protect skeletal muscles against damage from trauma or disease, treat shock, preserve donor tissue or organs; greater half-life CV THERAPEUTICS, INC. 2003-04-22 US disclosed